Clinical Trial

A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy

Study acronym: SPARROW-GC
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-site, open-label, randomized pilot feasibility study conducted at The Ottawa Hospital Cancer Centre. A total of 10 participants will be randomized 1:1 to either the experimental or control arm. The purpose of this study is to evaluate recruitment capability, intervention adherence, data completeness, and safety prior to consideration of a potential future multi-centre randomized trial.
Trial Details
NCT Number NCT07662200
Lead Sponsor Ottawa Hospital Research Institute
Conditions Germ Cell Cancer
Enrollment 10 participants
Start Date 2026-08
Primary Completion 2027-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-23